Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Jan Cerny"'
Publikováno v:
Cancer Management and Research
Platelet-derived growth factor-beta (PDGFRB) gene maps for the receptor tyrosine kinase PDGRFβ. PDGFRB gene fusions have been implicated in multiple myeloid and lymphoid neoplasms and have shown exquisite sensitivity to tyrosine kinase inhibitors. W
Publikováno v:
Leukemia & Lymphoma. 62:2022-2025
Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 25% of non-Hodgkin lymphoma cases [1]. Although often treatment-responsive, 30–40% of DLBCL patients develop refractory or relapsed ...
Publikováno v:
International Medical Case Reports Journal
Bacillus Calmette–Guérin (BCG) has been studied in various cancers for its immune modulation. Although the mechanism is yet to be completely understood, we do have positive experiences in many oncological cases. Hereby, we present a case of an 82-
Autor:
Neel S. Bhatt, Amer Beitinjaneh, J Kwok, S Ganguly, S Gerull, Ibrahim Ahmed, R T Kamble, Ruta Brazauskas, Anita J. Kumar, Christopher Bredeson, Nosha Farhadfar, S Hong, Theresa Hahn, Sachiko Seo, Richard F. Olsson, Matthew L. Ulrickson, Leo F. Verdonck, Yoshiko Atsuta, Anna Barata, Usama Gergis, David A. Rizzieri, Baldeep Wirk, Jennifer M. Knight, H. Schouten, Y. Inamoto, Jan Cerny, Wael Saber, Tamila L. Kindwall-Keller, Hemant S. Murthy, David Buchbinder, Keith M. Sullivan, David Szwajcer, Naya He, J Tay, M Aljurf, Stefan O. Ciurea, Saurabh Chhabra, Jignesh Dalal, Hillard M. Lazarus, Anita D'Souza, Amir Steinberg, Sara Beattie, Nandita Khera, Cesar O. Freytes, Medhat Askar, M Angel Diaz-Perez, Sherif M. Badawy, Y N Koleva, Jeff Szer, Hélène Schoemans, William A. Wood, Jean A. Yared
Publikováno v:
Current Oncology; Volume 27; Issue 6; Pages: 596-606
Curr Oncol
Current Oncology, 27(6), E596-E606. Multimed Inc.
Curr Oncol
Current Oncology, 27(6), E596-E606. Multimed Inc.
BACKGROUND: Evidence about the impact of marital status before hematopoietic cell transplantation (hct) on outcomes after hct is conflicting. METHODS: We identified patients 40 years of age and older within the Center for International Blood and Marr
Autor:
Wael Saber, Ann E. Woolfrey, Tamila L. Kindwall-Keller, Uday R. Popat, Melhem Solh, Mahmoud Aljurf, Robert Peter Gale, Ryotaro Nakamura, Taiga Nishihori, Bipin N. Savani, Mark R. Litzow, Amer Beitinjaneh, Rammurti T. Kamble, Richard F. Olsson, Sachiko Seo, Jean A. Yared, Jeff Szer, Jane L. Liesveld, Usama Gergis, Betty K. Hamilton, Zhen-Huan Hu, Siddhartha Ganguly, Jan Cerny, Soyoung Kim, Jean-Yves Cahn, Edward A. Copelan, Edwin P. Alyea, Leo F. Verdonck, Biju George, Shahrukh K. Hashmi, Shahinaz M. Gadalla, Aaron T. Gerds, Ying Liu, Bart L. Scott, Gerhard C. Hildebrandt, Baldeep Wirk, Vikas Gupta, Ronald Sobecks, Richard T. Maziarz, Hillard M. Lazarus, David A. Rizzieri, Ulrike Bacher
Publikováno v:
Blood Advances. 4:4748-4757
Comparative outcomes of allogeneic hematopoietic cell transplantation (HCT) for BCR-ABL1− myeloproliferative neoplasms (MPNs) in blast phase (MPN-BP) vs de novo acute myeloid leukemia (AML), and AML with prior myelodysplastic syndromes (MDSs; post-
Publikováno v:
Acta Haematologica. 144:297-301
Acute myeloid leukemia (AML) is a stem cell malignancy that originates in the bone marrow and involves the peripheral blood. Extramedullary AML is rarer, but it is most commonly associated with the former French-American-British (FAB) subtypes M4 or
Autor:
Siddhartha Ganguly, Andrew Daly, Tracey A. O'Brien, Melhem Solh, Steven Z. Pavletic, Rammurti T. Kamble, Leslie Lehmann, Tao Wang, Takanori Teshima, Amer Beitinjaneh, Miguel Pérez, Mahmoud Aljurf, Mukta Arora, John L. Wagner, Medhat Askar, Marjolein van der Poel, Madan Jagasia, Rabi Hanna, Alvaro Urbano-Ispizua, Ravi Vij, Armin Rashidi, Taiga Nishihori, Catherine J. Lee, A. Samer Al-Homsi, Vijaya Raj Bhatt, Michael T. Hemmer, Roger Strair, Hannah Choe, Joseph Pidala, Jeffery J. Auletta, Hisham Abdel-Azim, Vaibhav Agrawal, Shahinaz M. Gadalla, Stefan O. Ciurea, S Spellman, Margaret L. MacMillan, Rodrigo Martino, Jean-Yves Cahn, Mitchell S. Cairo, Basem M. William, Rizwan Romee, Jean A. Yared, Navneet S. Majhail, Annie Im, Usama Gergis, Mohamed A. Kharfan-Dabaja, Richard F. Olsson, Sagar S. Patel, Baldeep Wirk, Peiman Hematti, Michael Byrne, Asad Bashey, Hemant S. Murthy, Betty K. Hamilton, Muna Qayed, Pooja Khandelwal, Robert Peter Gale, Saurabh Chhabra, Gerhard C. Hildebrandt, Jan Cerny, Sachiko Seo, Roger H. Herzig, Nosha Farhadfar, Deepesh Lad, Hélène Schoemans, Akshay Sharma, Tim Prestidge, Lazaros J. Lekakis, Daniel J. Weisdorf, Paul Castillo, Miguel-Angel Perales
Publikováno v:
Biol Blood Marrow Transplant
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Biology of Blood and Marrow Transplantation, 26(8), 1459-1468. Elsevier Science
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Biology of Blood and Marrow Transplantation, 26(8), 1459-1468. Elsevier Science
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVH
Autor:
Michael Byrne, Jane L. Liesveld, Richard F. Olsson, Sagar S. Patel, Hongtao Liu, Eric Wong, Brenda M. Sandmaier, Bipin N. Savani, Hannah Choe, Partow Kebriaei, Gulrayz Ahmed, Tania Jain, Moussab Damlaj, Rebecca L. Olin, Mehdi Hamadani, Uday R. Popat, Neil Palmisiano, Rajneesh Nath, Mei-Jie Zhang, Mark R. Litzow, Attaphol Pawarode, Mark P. Hertzberg, Taiga Nishihori, Arnon Nagler, Jean A. Yared, Mitchell S. Cairo, Ioannis Politikos, Michael R. Grunwald, Hisham Abdel-Azim, Usama Gergis, David A. Rizzieri, Baldeep Wirk, Ashish Bajel, Rammurti T. Kamble, Hemant S. Murthy, Jean-Yves Cahn, Corey Cutler, Mahmoud Aljurf, A. Samer Al-Homsi, Geoffrey L. Uy, Miguel-Angel Perales, Muhammad Waqas Khan, Miguel Angel Diaz, Minocher Battiwalla, Mohamed A. Kharfan-Dabaja, Nosha Farhadfar, Natasha Kekre, Vaibhav Agrawal, Hillard M. Lazarus, Jan Cerny, Rodrigo Martino, Nandita Khera, Youjin Wang, Asmita Mishra, Nasheed Hossain, Luis Isola, Leo F. Verdonck, Nirav N. Shah, Vijaya Raj Bhatt, Zachariah DeFilipp, Daniel J. Weisdorf, Vikram Mathews, Edward A. Copelan, Aaron T. Gerds, C. Esar O. Freytes, David Valc A. Arcel, Shahrukh K. Hashmi, Mrinal M. Patnaik, Sunita Nathan, Sachiko Seo, Marcos de Lima, Qaiser Bashir, David I. Marks, Zheng Zhou, Yoshihiro Inamoto, Ryotaro Nakamura, Hai-Lin Wang, Edmund K. Waller, James M. Foran, Gerhard C. Hildebrandt, Amer Assal, Zartash Gul, Hassan B. Alkhateeb, Ulrike Bacher, Wael Saber
Publikováno v:
Blood Advances
There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center
Autor:
Narendranath Epperla, Ang Li, Brent Logan, Caitrin Fretham, Saurabh Chhabra, Mahmoud Aljurf, Lynette Chee, Edward Copelan, César O. Freytes, Peiman Hematti, Hillard M. Lazarus, Mark Litzow, Taiga Nishihori, Richard F. Olsson, Tim Prestidge, Wael Saber, Baldeep Wirk, Jean A. Yared, Alison Loren, Marcelo Pasquini, Allistair A. Abraham, Vaibhav Agrawal, Medhat Askar, Pere Barba, Alice Bertaina, Jean‐Yves Cahn, Jan Cerny, Hannah K. Choe, Miguel Angel Diaz, Christopher Dvorak, Nosha Farhadfar, Shahinaz M. Gadalla, Usama Gergis, Siddhartha Ganguly, Shahrukh Hashmi, Kimberly A. Kasow, Sunita Nathan, Roomi Nusrat, Sachiko Seo, Niketa C. Shah
Publikováno v:
British Journal of Haematology. 189:1171-1181
Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of allogeneic transplantation (allo-HCT). The incidence and risk factors associated with TA-TMA are not well known. A retrospective analysis from the Center for International
Autor:
Ulrike Bacher, Wael Saber, Uday R. Popat, Amer Beitinjaneh, Richard Gopez Ancheta, Shahinaz M. Gadalla, Jean-Yves Cahn, Ying Liu, Michael R. Grunwald, Hillard M. Lazarus, Jeff Szer, Naeem Chaudhri, Hisham Abdel-Azim, Nasheed Hossain, Richard F. Olsson, Gerhard C. Hildebrandt, Melhem Solh, Ronald Sobecks, Jacob M. Rowe, Shahrukh K. Hashmi, Zhen-Huan Hu, Jack W. Hsu, Yoshihiro Inamoto, Aaron T. Gerds, Harry C. Schouten, Mohamed A. Kharfan-Dabaja, Muthalagu Ramanathan, Matt Kalaycio, Jane L. Liesveld, Jan Cerny, David S. Snyder, Zachariah DeFilipp, Taiga Nishihori, Mark B. Juckett, Celalettin Ustun, Andrew Daly, Ashish Bajel, Mahmoud Aljurf, Bipin N. Savani, Rammurti T. Kamble, Mehdi Hamadani, Kirk R. Schultz, Mark R. Litzow, Mary Lynn Savoie, Ran Reshef, Jean A. Yared, Siddhartha Ganguly, Robert Peter Gale, Sachiko Seo, Edwin P. Alyea
Publikováno v:
Biol Blood Marrow Transplant
Biology of Blood and Marrow Transplantation, 26(3), 472-479. Elsevier Science
Biology of Blood and Marrow Transplantation, 26(3), 472-479. Elsevier Science
It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia (CML).